Please use this identifier to cite or link to this item:
Title: Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study.
Austin Authors: Lin, Tiffany;Pham, Jonathan;Paul, Eldho;Conron, Matthew;Wright, Gavin;Ball, David;Mitchell, Paul L R ;Atkin, Nicola;Brand, Margaret;Zalcberg, John;Stirling, Robert G
Affiliation: Olivia Newton-John Cancer Wellness and Research Centre
Department of Medicine, Monash University, Melbourne, Australia
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Department of Respiratory Medicine, Alfred Hospital, Melbourne, Australia
Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre, Melbourne, Australia
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Victorian Comprehensive Cancer Centre, Melbourne, Australia
Department of Respiratory Medicine, St Vincent's Hospital, Melbourne, Australia
Issue Date: Jan-2022 2021-12-10
Publication information: Lung Cancer 2022; 163: 69-76
Abstract: Multidisciplinary Meetings (MDM) are recommended in routine lung cancer care, however its broader impacts demand further evaluation. We assessed the drivers and impacts of MDM presentation in the Victorian Lung Cancer Registry (VLCR). We examined the effect of MDM presentation on receipt of treatment and survival in VLCR patients diagnosed between 2011 and 2020. We compared patient characteristics, drivers of MDM discussion and survival between the two groups. Of 9,628 patients, 5,900 (61.3%) were discussed at MDM, 3,728 (38.7%) were not. In the non-MDM group, a lower proportion received surgery (22.1% vs. 31.2%), radiotherapy (34.2% vs. 44.4%) and chemotherapy (44.7% vs. 49.0%). Patients were less likely to be discussed if ≥80 years (OR 0.73, p < 0.001), of ECOG performance status (PS) 4 (OR 0.23, p < 0.001), clinical stage IV (OR 0.34, p < 0.001) or referred from regional (OR 0.52, p < 0.001) or private hospital (OR 0.18, p < 0.001). MDM-presented patients had better median survival (1.70 vs 0.75 years, p < 0.001) and lower adjusted mortality risk (HR 0.75; 0.71-0.80, p < 0.001), a protective effect consistent across all hospital types. Undocumented PS, histopathology and clinical stage were associated with lower likelihood of MDM discussion and worse mortality. In the VLCR, being male, ≥80 years, of poorer PS, advanced clinical stage and poor clinical characterisation significantly disadvantaged patients in relation to MDM discussion. MDM-discussed patients were more likely to undergo treatment and had a 25% lower risk of mortality. This study supports the use of MDMs in lung cancer and identifies areas of inequity to be addressed.
DOI: 10.1016/j.lungcan.2021.12.006
Journal: Lung Cancer (Amsterdam, Netherlands)
PubMed URL: 34923204
PubMed URL:
Type: Journal Article
Subjects: Equity
Health policy
Health services research
Learning health system
Lung cancer
Multidisciplinary meeting
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 9, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.